Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 5, 2007, Pages 906-913

  Cho, Monique E ^a   Smith, David C ^a   Branton, Mary H ^a   Penzak, Scott R ^b   Kopp, Jeffrey B ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE; PYRIDONE DERIVATIVE;

ADULT; AGED; ARTICLE; DRUG EFFECT; FEMALE; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PILOT STUDY; PROSPECTIVE STUDY;

ADULT; AGED; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRIDONES;

EID: 34548834734     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01050207     Document Type: Article

References (37)

1. Kitiyakara C, Eggers P, Kopp JB: Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 44: 815-825, 2004
2. Barisoni LA, Schnaper HW, Kopp JB: A proposed taxonomy for the podocytopathies: A reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol 2: 529-542, 2007
3. Korbet SM: Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis. Semin Nephrol 23: 219-228, 2003
4. Cattran DC: Cyclosporine in the treatment of idiopathic focal segmental glomerulosclerosis. Semin Nephrol 23: 234-241, 2003
5. Mitch WE, Walser M, Buffington GA, Lemann J Jr: A simple method of estimating progression of chronic renal failure. Lancet 2: 1326-1328, 1976
6. Lewis J, Greene T, Appel L, Contreras G, Douglas J, Lash J, Toto R, Van Lente F, Wang X, Wright JT Jr: A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension. J Am Soc Nephrol 15: 3175-3183, 2004
7. Cain WC, Stuart RW, Lefkowitz DL, Starnes JD, Margolin S, Lefkowitz SS: Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int J Immunopharmacol 20: 685-695, 1998
8. Giri SN, Leonard S, Shi X, Margolin SB, Vallyathan V: Effects of pirfenidone on the generation of reactive oxygen species in vitro. J Environ Pathol Toxicol Oncol 18: 169-177, 1999
9. Al-Bayati MA, Xie Y, Mohr FC, Margolin SB, Giri SN: Effect of pirfenidone against vanadate-induced kidney fibrosis in rats. Biochem Pharmacol 64: 517-525, 2002
10. Giri SN, Al-Bayati MA, Du X, Schelegle E, Mohr FC, Margolin SB: Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats. Cancer Chemother Pharmacol 53: 141-150, 2004
11. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L: Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 133: 687-694, 2001
12. Park HS, Bao L, Kim YJ, Cho IH, Lee CH, Hyun BH, Margolin SB, Park YH: Pirfenidone suppressed the development of glomerulosclerosis in the FGS/ Kist mouse. J Korean Med Sci 18: 527-533, 2003
13. Shimizu F, Fukagawa M, Yamaguchi Y, Taniyama M, Komemushi S, Margolin S, Kurokawa K: Pirfenidone prevents the progression of irreversible glomerular sclerotic lesions in rats. Nephrology 3: 315-322, 1997
14. Shimizu T, Kuroda T, Hata S, Fukagawa M, Margolin SB, Kurokawa K: Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 54: 99-109, 1998
15. Shimizu T, Fukagawa M, Kuroda T, Hata S, Iwasaki Y, Nemoto M, Shirai K, Yamauchi S, Margolin SB, Shimizu F, Kurokawa K: Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int Suppl 63: S239-S243, 1997
16. Armendariz-Boruncla J, Islas-Carbajal MC, Meza-Garcia E, Rincon AR, Lucano S, Sandoval AS, Salazar A, Berumen J, Alvarez A, Covarrubias A, Arechiga G, Garcia L: A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut 55: 1663-1665, 2006
17. Walker JE, Giri SN, Margolin SB: A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis. Mult Scler 11: 149-158, 2005
18. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, Sato A, Kudoh S: Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171: 1040-1047, 2005
19. Gahl WA, Brantly M, Troendle J, Avila NA, Padua A, Montalvo C, Cardona H, Calis KA, Gochuico B: Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab 76: 234-242, 2002
20. Levey AS, Greene T, Kusek JW, Beck GJ: A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol 11: 155A, 2000
21. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD: Obesity-related glomerulopathy: An emerging epidemic. Kidney Int 59: 1498-1509, 2001
22. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 331: 1286-1292, 1994
23. Yamamoto T, Noble NA, Miller DE, Border WA: Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int 45: 916-927, 1994
24. Kim JH, Kim BK, Moon KC, Hong HK, Lee HS: Activation of the TGF-beta/ Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int 64: 1715-1721, 2003
25. Iyer SN, Gurujeyalakshmi G, Giri SN: Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 291: 367-373, 1999
26. Shihab FS, Bennett WM, Yi H, Andoh TF: Pirfenidone treatment decreases transforming growth factor-betal and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant 2: 111-119, 2002
27. Brook NR, Waller JR, Bicknell GR, Nicholson ML: The novel antifibrotic agent pirfenidone attenuates the profibrotic environment generated by calcineurin inhibitors in the rat salt-depletion model. Transplant Proc 37: 130-133, 2005
28. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361: 117-124, 2003
29. Remuzzi G, Perico N, Macia M, Ruggenenti P: The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 99: S57-S65, 2005
30. Ziyadeh IN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 97: 8015-8020, 2000
31. Leh S, Vaagnes O, Margolin SB, Iversen BM, Forslund T: Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats. Nephrol Dial Transplant 20: 71-82, 2005
32. Morton V, Torgerson DJ: Regression to the mean: Treatment effect without the intervention. J Eval Clin Pract 11: 59-65, 2005
33. Brenner BM, Cooper ME, de Zeeuw D, Keane WE, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
34. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
35. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462, 1993
36. Bowen JD, Maravilla K, Margolin SB: Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis. Mult Scler 9: 280-283, 2003
37. Nagai S, Hamada K, Shigematsu M, Taniyama M, Yamauchi S, Izumi T: Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 41: 1118-1123, 2002